The FDA has expanded the indication for Toujeo (insulin glargine; Sanofi) 300 Units/mL to include treatment of pediatric patients aged ≥6 years with diabetes mellitus. The Food and Drug Administration ...

* CHMP adopts positive opinion for expanded indication for Toujeo in children and adolescents (aged 6 to 17 years) with diabetes The trial, EDITION JUNIOR, is the first randomized, controlled trial ...

Sanofi (Euronext: SAN; NYSE: SNY) announced today that it received FDA approval for its Toujeo Max SoloStar insulin pen, the highest capacity long-acting insulin pen that will be available on the ...

SaveHealth reports that insulin therapy is crucial for diabetes management, with various options available, including rapid- and long-acting insulins.

PARIS (Reuters) - French drugmaker Sanofi plans to launch its new Toujeo insulin for diabetics in the United States on Monday, according to a source familiar with the matter. Toujeo was approved for ...

The FINANCIAL — Sanofi announced on February 26 that the U.S. Food and Drug Administration (FDA) approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal ...

The FINANCIAL — Sanofi announced on April 28 that the European Commission has granted marketing authorization in Europe for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a ...

A century ago, type 1 diabetes was a death sentence. Children diagnosed rarely survived more than a year or two, wasting away as their bodies starved despite food. Then, in 1921, in a modest lab in ...

Mainers who rely on insulin will now be eligible to purchase monthly supplies of Sanofi insulin products through 2029 for $35 cash, under a new settlement announced by Attorney General Aaron Frey. The ...

Medically reviewed by Mary Choy, PharmD Key Takeaways Insulin is needed to manage your blood sugar levels if you have type 1 ...